Dexcom, a company that makes medical devices, announced that it got a warning letter from the U.S. Food and Drug Administration after inspections of its two main manufacturing sites. This news caused its stock to drop by almost 7% after trading hours.
DexCom, Inc. (NASDAQ:DXCM) will participate in the 46th Annual Raymond James Institutional Investors Conference on March 4, 2025, at 10:25 AM ET. The company will be represented by Jereme Sylvain, the Chief Financial Officer, and Matt Carey, the Manager of Investor Relations. Jayson Bedford from Raymond James will also be joining the conference call.
To increase your wealth and get ready for retirement, it's wise to invest in strong growth stocks for the long term. As these companies consistently increase their revenue and profits, their value rises, leading investors to pay higher prices for their shares.
On Thursday, Dexcom, Inc. reported that its revenue for the fourth quarter increased by 8% compared to the same period last year, reaching $1.114 billion. This amount was higher than the analysts' average prediction of $1.104 billion.
On Thursday, DexCom, Inc. DXCM announced that its earnings for the fourth quarter were lower than anticipated.
DXCM's earnings for the fourth quarter of 2024 have dropped, even though sales have gone up. In 2025, the company is predicted to do better due to the worldwide rise in CGM use, strong sales of sensors, and entry into new markets.
DexCom (DXCM 0.26%), a company recognized for its continuous glucose monitoring (CGM) systems, recently announced its Q4 2024 earnings on February 13, 2025. The report showed an 8% increase in revenue, totaling $1.114 billion, which was just above analysts' predictions of $1.112 billion.
The main figures for DexCom (DXCM) provide an overview of the company's performance for the quarter that ended in December 2024. However, it could be useful to compare some important metrics with Wall Street predictions and the results from the same period last year.
DexCom (DXCM) reported quarterly earnings of $0.45 per share, which is lower than the Zacks Consensus Estimate of $0.50 per share. This is a decrease compared to earnings of $0.50 per share from the same period last year.
Dexcom, a company that makes medical devices, exceeded sales expectations for the fourth quarter due to strong demand for its continuous glucose monitors (CGMs) used by diabetes patients.